19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      TNF-α/IL-1β–licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell–mediated induction of Foxp3+ regulatory T cells in the lung

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d9691835e160">Mesenchymal stromal cells (MSCs) have shown promise as a therapy for immune-mediated disorders, including transplant rejection. Our group previously demonstrated the efficacy of pretransplant, systemic administration of allogeneic but not syngeneic MSCs in a rat cornea transplant model. The aim of this study was to enhance the immunomodulatory capacity of syngeneic MSCs. In vitro, MSCs licensed with TNF-α/IL-1β (MSCsTNF-α/IL-1β) suppress syngeneic lymphocyte proliferation via NO production. In vivo, when administered post-transplantation, nonlicensed syngeneic MSCs improved graft survival from 0 to 50% and MSCsTNF-α/IL-1β, in an NO-dependent manner, improved survival to 70%. Improved survival was associated with increased CD4+CD25+forkhead box P3+ regulatory T (Treg) cells and decreased proinflammatory cytokine expression in the draining lymph node. MSCsTNF-α/IL-1β demonstrated a more potent immunomodulatory capacity compared with nonlicensed MSCs, promoting an immune-regulatory CD11b+B220+ monocyte/macrophage population and significantly expanding Treg cells in the lungs and spleen. Ex vivo, we observed that lung-derived myeloid cells act as intermediaries of MSC immunomodulatory function. MSC-conditioned myeloid cells suppressed stimulated lymphocyte proliferation and promoted expansion of Treg cells from naive lymphocytes. This work illustrates how syngeneic MSC therapy can be enhanced by licensing and optimization of timing strategies and further highlights the important role of myeloid cells in mediating MSC immunomodulatory capacity.-Murphy, N., Treacy, O., Lynch, K., Morcos, M., Lohan, P., Howard, L., Fahy, G., Griffin, M. D., Ryan, A. E., Ritter, T. TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung. </p>

          Related collections

          Author and article information

          Journal
          The FASEB Journal
          The FASEB Journal
          Wiley
          0892-6638
          1530-6860
          August 2019
          August 2019
          : 33
          : 8
          : 9404-9421
          Affiliations
          [1 ]Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland–Galway, Galway, Ireland;
          [2 ]Discipline of Pharmacology and Therapeutics, School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland–Galway, Galway, Ireland;
          [3 ]Department of Ophthalmology, University Hospital Galway, National University of Ireland–Galway, Galway, Ireland;
          [4 ]Centre for Research in Medical Devices (CÚRAM), School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland–Galway, Galway, Ireland
          Article
          10.1096/fj.201900047R
          31108041
          93486472-0dcd-413f-a820-9e115557727e
          © 2019
          History

          Comments

          Comment on this article